PrintThe Burrill Report (August 11, 2014): Therapeutic Vaccine for Parkinson's Disease Shows Early Promise (.JPG,24.32 Kb)
The biotechnology company Affiris recently announced encouraging early-stage results for a therapeutic vaccine for Parkinson’s disease. The trial, backed by the Michael J. Fox Foundation, is the first clinical trial of a therapeutic to target alpha-synuclein, a protein abundant in the brain that may play a role in the development of the disease. We spoke to Kuldip Dave, director of research programs for the Michael J. Fox Foundation, about the Affiris trial, what the results tell us, and why alpha-synuclein may be a compelling target in the fight against Parkinson’s disease.August 06, 2014
http://www.burrillreport.com/article-therapeutic_vaccine_for_parkinsons_disease_shows_early_promise_.html
